Cas:412034-89-0 tetracyclo[3.2.1.01,3.02,7]octane-2-carboxamide manufacturer & supplier

Chemical Name:tetracyclo[3.2.1.01,3.02,7]octane-2-carboxamide

CAS.NO:412034-89-0

Synonyms:tetracyclo[3.2.1.01,3.02,7]octane-2-carboxamide

Molecular Formula:C₉H₁₁NO

Molecular Weight:149.19000

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:44.08000

Exact Mass:149.08400

LogP:1.66750

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like tetracyclo[3.2.1.01,3.02,7]octane-2-carboxamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,tetracyclo[3.2.1.01,3.02,7]octane-2-carboxamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,tetracyclo[3.2.1.01,3.02,7]octane-2-carboxamide Use and application,tetracyclo[3.2.1.01,3.02,7]octane-2-carboxamide technical grade,usp/ep/jp grade.

Related News: In August, the Company announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 10,370,452 covering compositions and uses of effector T cells expressing a CAR, where such T cells are derived from a pluripotent stem cell, including an iPSC. tetracyclo[3.2.1.01,3.02,7]octane-2-carboxamide manufacturer ICIG is a privately owned industrial holding company focusing on mid-sized chemicals and pharmaceutical businesses. tetracyclo[3.2.1.01,3.02,7]octane-2-carboxamide supplier As a result, the Company��s platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy. tetracyclo[3.2.1.01,3.02,7]octane-2-carboxamide vendor As a result, the Company��s platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy. tetracyclo[3.2.1.01,3.02,7]octane-2-carboxamide factory Nearly all patients who got the vaccine developed antibodies designed to head off the spread of abnormal tau while leaving healthy tau proteins intact, Novak said.